Dermata Therapeutics, Inc. (DRMA)
About Dermata Therapeutics, Inc.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$7.6M
- Total assets
- $7.9M
- Market cap
- $4.7M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $7.8M
- Operating income
- -$7.8M
- Net income
- -$7.6M
- EPS (basic)
- $-8.16
- EPS (diluted)
- $-8.16
Balance sheet
- Total assets
- $7.9M
- Current assets
- $7.9M
- Total liabilities
- $1.6M
- Current liabilities
- $1.6M
- Shareholders’ equity
- $6.2M
Cash flow
- Operating cash flow
- -$7.8M
- Investing cash flow
- -$4.4M
- Financing cash flow
- $12.1M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.7M
- EPS (diluted)
- $-8.16
- Shares outstanding
- 3.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 13, 2021
Dermata Therapeutics, Inc. (DRMA) Stock Price
- Reported a net loss of $7.6M.
- Trading 82% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Dermata Therapeutics, Inc..
Write a review
News about Dermata Therapeutics, Inc.
News & sentiment via Polygon.io
Dermata Therapeutics, Inc.: frequently asked questions
Is Dermata Therapeutics, Inc. an American company?
Dermata Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Dermata Therapeutics, Inc. headquartered?
Dermata Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Dermata Therapeutics, Inc. publicly traded?
Yes — Dermata Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol DRMA on the NASDAQ.
What does Dermata Therapeutics, Inc. do?
Dermata Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
